(NASDAQ: BCRX) Biocryst Pharmaceuticals's forecast annual revenue growth rate of 10.14% is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 108.62%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 25.33%.
Biocryst Pharmaceuticals's revenue in 2025 is $557,506,000.On average, 13 Wall Street analysts forecast BCRX's revenue for 2025 to be $133,943,928,770, with the lowest BCRX revenue forecast at $127,753,375,289, and the highest BCRX revenue forecast at $139,107,971,348. On average, 13 Wall Street analysts forecast BCRX's revenue for 2026 to be $142,311,357,110, with the lowest BCRX revenue forecast at $126,724,765,182, and the highest BCRX revenue forecast at $155,122,800,953.
In 2027, BCRX is forecast to generate $156,376,025,920 in revenue, with the lowest revenue forecast at $136,187,978,167 and the highest revenue forecast at $173,413,168,019.